Corindus Vascular Robotics, Inc. 8-K


Exhibit 10.1


 





 


SECURITIES
PURCHASE AGREEMENT


 


This
Securities Purchase Agreement (this “Agreement”) is dated as of February 26, 2019, by and
between Corindus Vascular Robotics, Inc., a Delaware corporation (the “Company”), and each Purchaser
identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser”
and collectively, the “Purchasers”).


 


Recitals


 


A.          This
Agreement is being executed by the Company and each Purchaser in connection with the private placement offering (the “Offering”)
of the common stock, par value $0.0001 per share, of the Company (the “Common Stock”), at the Purchase
Price per share.


 


B.          The
Company and each Purchaser is executing and delivering this Agreement in reliance upon an exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or
Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission
(the “Commission”) under the Securities Act.


 


C.          Each
Purchaser, severally and not jointly, wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated
in this Agreement, that aggregate number of shares of Common Stock, determined as set forth in Section 2.1(a) below
(which aggregate amount for all Purchasers together shall be collectively referred to herein as the “Shares”).


 


D.          Prior
to the Closing, the parties hereto will execute and deliver a Registration Rights Agreement, substantially in the form attached
hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which, among other
things, the Company will agree to provide, with respect to the Shares, certain registration rights under the Securities Act and
the rules and regulations promulgated thereunder and applicable state securities laws.


 


Now,
Therefore, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers hereby agree as follows:


 


Article
1

DEFINITIONS


 


1.1             
Definitions. In addition to the terms defined elsewhere
in this Agreement, for all purposes of this Agreement, the following terms shall have the meanings indicated in this Section 1.1:



 


“Action”
means any action, suit, inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation
pending or, to the Company’s Knowledge, threatened in writing (or otherwise) against the Company or any of its Subsidiaries
or properties or any officer, director or employee of the Company as of the date hereof acting in his or her capacity as an officer,
director or employee of the Company before or by any federal, state, county, local or foreign court, arbitrator, governmental or
administrative agency, regulatory authority, stock market, stock exchange or trading facility.


 


“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, Controls,
is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 144. With
respect to a Purchaser, any investment fund or managed account that is managed on a discretionary basis by the same investment
manager as such Purchaser will be deemed to be an Affiliate of such Purchaser.


 






    


    


    

 


“Agreement”
has the meaning set forth in the preamble.


 


“Applicable
Laws” has the meaning set forth in Section 3.1(o).


 


“Board”
means the Board of Directors of the Company.


 


“Boston
Courts” means the state and federal courts sitting in Boston, Massachusetts.


 


“Business
Day” means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or any
day on which banking institutions in the Commonwealth of Massachusetts are authorized or required by law or other governmental
action to close.


 


“Closing”
means the closing of the purchase by the Purchasers and sale by the Company of the Shares to such Purchasers pursuant to this Agreement.


 


“Closing
Date” means the Trading Day when all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all of the conditions set forth in Sections 2.1, 2.2, 5.1 and 5.2 hereof are satisfied
or waived by the Purchasers holding or having the right to acquire at least a majority of the Shares to be purchased at the Closing
or then outstanding, as the case may be, or such other date as the Company and such Purchasers may agree.


 


“Commission”
has the meaning set forth in the Recitals.


 


“Common
Stock” has the meaning set forth in the Recitals.


 


“Company”
has the meaning set forth in the preamble.


 


“Company
Counsel” means Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., with offices located at One Financial Center,
Boston, Massachusetts 02111.


 


“Company
Deliverables” has the meaning set forth in Section 2.2(a).


 


“Company
Product” has the meaning set forth in Section 3.1(p).


 


“Company’s
Knowledge” means with respect to any statement made to the knowledge of the Company, that the statement is based
upon the actual knowledge of the officers of the Company who, as of the date hereof, have responsibility for the matter or matters
that are the subject of the statement, and the knowledge that each such person would have reasonably obtained in the performance
of each such person's duties as an officer of the Company.


 


“Compliance
Certificate” has the meaning set forth in Section 2.2(a)(vi).


 


“Control”
(including the terms “controlling”, “controlled” by or “under common
control with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management
and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.


 


“Covered
Persons” has the meaning set forth in Section 3.1(ll).


 


“Disclosure
Materials” has the meaning set forth in Section 3.1(h).


 






    2


    


    

 


“Disclosure
Schedule” has the meaning set forth in Section 3.1.


 


“Disqualification
Events” has the meaning set forth in Section 3.1(ll).


 


“DTC”
has the meaning set forth in Section 4.1(d).


 


“Environmental
Laws” has the meaning set forth in Section 3.1(l).


 


“Evaluation
Date” has the meaning set forth in Section 3.1(u).


 


“ERISA”
has the meaning set forth in Section 3.1(ii).


 


“Exchange
Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations
promulgated thereunder.


 


“FDA”
has the meaning set forth in Section 3.1(o).


 


“GAAP”
means U.S. generally accepted accounting principles, as applied by the Company.


 


“Indemnified
Person” has the meaning set forth in Section 4.8(b).


 


“Intellectual
Property” has the meaning set forth in Section 3.1(r).


 


“Irrevocable
Transfer Agent Instructions” means, with respect to the Company, the Irrevocable Transfer Agent Instructions, in
the form of Exhibit E, executed by the Company and delivered to and acknowledged in writing by the Transfer Agent.


 


“Lien”
means any material lien, charge, claim, encumbrance, security interest, right of first refusal, preemptive right or other restrictions
of any kind.


 


“Material
Adverse Effect” means a material adverse effect on the (i) validity or enforceability of, or the Company’s
ability to perform in any material respect its obligations under, this Agreement or (ii) earnings, results of operations, assets,
properties, business or condition (financial or otherwise) of the Company and its subsidiaries, taken as a whole, except that any
of the following, either alone or in combination, shall not be deemed a Material Adverse Effect: (i) effects caused by changes
or circumstances affecting general market conditions in the U.S. or applicable foreign economy or effects generally applicable
to the industry in which the Company operates, (ii) effects resulting from or relating to the announcement or disclosure of
the sale of the Shares or other transactions contemplated by this Agreement, (iii) effects caused by any event, occurrence
or condition resulting from or relating to the taking of any action in accordance with this Agreement, (iv) changes
in the trading price or trading volume of the Company’s Common Stock (but not the underlying causes thereof), (v)
the filing of any stockholder or derivative litigation arising from or relating
to the execution of this Agreement or the consummation of the transactions contemplated hereby, or (vi) effects caused by earthquakes,
hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities,
acts of war, sabotage or terrorism or military actions existing as of the date hereof, except, with respect to clauses (i) and
(vi), to the extent that the effects of such changes or events are disproportionately adverse to the earnings, results of
operations, assets, properties, business or condition (financial or otherwise) of the Company and its subsidiaries, taken as a
whole.


 


“Material
Contract” means any contract of the Company that has been filed as an exhibit to the SEC Reports pursuant to Item 601(b)(4)
or Item 601(b)(10) of Regulation S-K.


 






    3


    


    

 


“Material
Permits” has the meaning set forth in Section 3.1(p).


 


“Money
Laundering Laws” has the meaning set forth in Section 3.1(ff).


 


“Outside
Date” means the tenth (10th) Business Day following the date of this Agreement.


 


“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.


 


“Principal
Trading Market” means the Trading Market on which the Common Stock is primarily listed on or quoted for trading,
which, as of the date of this Agreement and the Closing Date, shall be the NYSE American.


 


“Proceeding”
means an Action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding,
such as a deposition).


 


“Purchase
Price” means $1.3796.


 


“Purchaser”
or “Purchasers” has the meaning set forth in the preamble.


 


“Purchaser
Deliverables” has the meaning set forth in Section 2.2(b).


 


“Purchaser
Party” has the meaning set forth in Section 4.8(a).


 


“Registration
Rights Agreement” has the meaning set forth in the recitals.


 


“Registration
Statement” means a registration statement meeting the requirements set forth in the Registration Rights Agreement
and covering the resale by the Purchasers of the Registrable Securities (as defined in the Registration Rights Agreement).


 


“Regulation
D” has the meaning set forth in the Recitals.


 


“Required
Approvals” has the meaning set forth in Section 3.1(e).


 


“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.


 


“Sanctions”
has the meaning set forth in Section 3.1(gg).


 


“Sanctioned
Persons” has the meaning set forth in Section 3.1(gg).


 


“Sanctioned
Country” and “Sanctioned Countries” have the meanings set forth in Section 3.1(gg).


 


“SEC Reports”
has the meaning set forth in Section 3.1(h).


 


“Secretary’s
Certificate” has the meaning set forth in Section 2.2(a)(vi).


 


“Securities
Act” has the meaning set forth in the recitals.


 






    4


    


    

 


“Shares”
has the meaning set forth in the Recitals.


 


“Short
Sales” include, without limitation, (i) (A) all “short sales” as defined in Rule 200 promulgated
under Regulation SHO under the Exchange Act, whether or not against the box, and (B) all types of direct and indirect stock
pledges, forward sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in
Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis) that have an economically
similar result to a “short sale” as defined in Rule 200, and (ii) sales and other transactions through non-U.S.
broker dealers or foreign regulated brokers that have an economically similar result to a “short sale” as defined in
Rule 200.


 


“Solicitor”
has the meaning set forth in Section 3.1(ll).


 


“Stock
Certificates” has the meaning set forth in Section 2.2(a)(iv).


 


“Subscription
Amount” has the meaning set forth in Section 2.1(a).


 


“Subsidiary”
means any entity in which the Company, directly or indirectly, owns capital stock or holds an equity or similar interest.


 


“Trading
Affiliate” has the meaning set forth in Section 3.2(h).


 


“Trading
Day” means (i) a day on which the Common Stock is listed or quoted and traded on its Principal Trading Market
(unless the Principal Trading Market is the OTC Bulletin Board or the OTC Pink tier of the OTC Markets Group, Inc.), or (ii) if
the Common Stock is not listed on a Trading Market (other than the OTC Bulletin Board or the OTC QB, OTC QX or OTC Pink tier of
the OTC Markets Group, Inc.), a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTC
Bulletin Board, or (iii) if the Common Stock is not quoted on any Trading Market (other than the OTC QB, OTC QX or OTC Pink
tier of the OTC Markets Group, Inc.), a day on which the Common Stock is quoted in the over-the-counter market as reported by the
OTC QB, OTC QX or OTC Pink tier of the OTC Markets Group, Inc. (or any similar organization or agency succeeding to its functions
of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) and
(iii) hereof, then Trading Day shall mean a Business Day.


 


“Trading
Market” means whichever of the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq
Global Market, the Nasdaq Capital Market, the OTC Bulletin Board, the OTC QB, OTC QX or OTC Pink tier of the OTC Markets Group,
Inc. (or any similar organization or agency succeeding to its functions of reporting prices) on which the Common Stock is listed
or quoted for trading on the date in question.


 


“Transaction
Documents” means this Agreement, the Registration Rights Agreement, the annexes and exhibits attached hereto and
thereto, the Irrevocable Transfer Agent Instructions and any other documents or agreements executed in connection with the transactions
contemplated hereunder.


 


“Transfer
Agent” means Manhattan Transfer Registrar Company, with a mailing address of 57 Eastwood Road, Miller Place, NY 11764,
or any successor transfer agent for the Company.


 


“Voting
Debt” has the meaning set forth in Section 3.1(g).


 






    5


    


    

 


Article
2

PURCHASE AND SALE


 


2.1                 Closing. 


 


(a)            
Subject to the terms and conditions set forth in this Agreement, at the Closing, the Company
shall issue and sell to each Purchaser, and each Purchaser shall, severally and not jointly, purchase from the Company, such number
of Shares equal to the quotient resulting from dividing (i) the Subscription Amount for such Purchaser, as indicated opposite
such Purchaser’s name on Exhibit A hereto (the “Subscription Amount”), by (ii) the
Purchase Price, rounded down to the nearest whole Share. 


 


(b)             The
Closing of the purchase and sale of the Shares shall take place at the offices of Company Counsel on the Closing Date or at such
other location(s) or remotely by electronic means as the Company and the Purchasers holding or having the right to acquire at
least a majority of the Shares to be purchased at the Closing mutually agree. 


 


(c)             
On the Closing Date, the Company shall deliver to each Purchaser (or its designated custodian
in accordance with its delivery instructions) a Stock Certificate (as defined below) representing the Shares being purchased by
such Purchaser hereunder (registered in the name of such Purchaser or its nominee as set forth on the Stock Certificate Questionnaire)
or evidence of a book entry position, free and clear of all restrictive and other legends or instructions (except as expressly
provided in Section 4.1(c) hereof), evidencing the number of Shares such Purchaser is purchasing hereunder, in each case
against payment by the Purchaser of its applicable Subscription Amount, in United States dollars and in immediately available funds,
by wire transfer to a bank account designated by the Company. Notwithstanding anything to the contrary set forth herein, no Purchaser
shall be required to pay its Subscription Amount for the Shares being purchased by such Purchaser until it (or its designated custodian
as set forth on the Stock Certificate Questionnaire) confirms receipt of a Stock Certificate or evidence of a book entry position
evidencing the Shares being purchased hereunder.


 


2.2             
  Closing Deliveries. 


 


(a)            
On or prior to the Closing, the Company shall issue, deliver or cause to be delivered
or made available to each Purchaser the following (the “Company Deliverables”): 


 


(i)                
this Agreement, duly executed by the Company;


 


(ii)              
a legal opinion of Company Counsel dated as of the Closing Date, in substantially the
form attached hereto as Exhibit D, executed by such counsel and addressed to the Purchasers;


 


(iii)            
the Registration Rights Agreement, duly executed by the Company;


 


(iv)            
one or more stock certificates, free and clear of all restrictive and other legends, except
as provided in Section 4.1(c) hereof, evidencing the Shares subscribed for by the Purchasers hereunder to be registered
in the name of such Purchasers as set forth on the Stock Certificate Questionnaire included as Exhibit C-2 hereto (the
“Stock Certificates”) and delivered to the Company pursuant to Section 2.2(b)(iv);


 






    6


    


    

 


(v)              
a certificate of the Secretary of the Company (the “Secretary Certificate”),
dated as of the Closing Date, (a) certifying the resolutions adopted by the Board of Directors of the Company and any duly
authorized committee thereof approving the transactions contemplated by this Agreement and the other Transaction Documents and
the issuance of the Shares, (b) certifying the current versions of the certificate of incorporation, as amended, and bylaws
of the Company and (c) certifying as to the signatures and authority of persons signing the Transaction Documents and related
documents on behalf of the Company, in substantially the form attached hereto as Exhibit F;


  


(vi)            
a certificate (the “Compliance Certificate”), dated as of the
Closing Date and signed by the Company’s Chief Executive Officer or its Chief Financial Officer, certifying to the fulfillment
of the conditions specified in Sections 5.1(a) and (b), in substantially the form attached hereto as Exhibit G;


 


(vii)          
a certificate evidencing the formation and good standing of the Company issued by the
Secretary of State of the State of Delaware, as of a date within five (5) days of the Closing Date; and


 


(viii)        
a certified copy of the Certificate of Incorporation, as certified by the Secretary of
State of the State of Delaware, as of a date within ten (10) days of the Closing Date.


 


(b)            
On or prior to the Closing, each Purchaser shall deliver or cause to be delivered to the
Company the following (the “Purchaser Deliverables”): 


 


(i)                
this Agreement, duly executed by such Purchaser;


 


(ii)              
the Registration Rights Agreement, duly executed by such Purchaser;


 


(iii)            
its Subscription Amount, in United States dollars and in immediately available funds,
by wire transfer to the account provided by the Company;


 


(iv)            
a fully completed and duly executed Selling Stockholder Questionnaire in the form attached
as Annex B to the Registration Rights Agreement;


 


(v)              
a fully completed and duly executed Accredited Investor Questionnaire in the form attached
hereto as Exhibit C-1; and


 


(vi)            
a fully completed and duly executed Stock Certificate Questionnaire in the form attached
hereto as Exhibit C-2.


 


Article
3

REPRESENTATIONS AND WARRANTIES


 


3.1             
 Representations and Warranties of the Company. The
Company hereby represents and warrants as of the date hereof and the Closing Date (except for the representations and warranties
that speak as of a specific date, which shall be made as of such date) to each of the Purchasers that except as disclosed in the
SEC Reports and the disclosure schedule delivered by the Company hereunder (the “Disclosure Schedule”),
which disclosure shall be deemed a part of this Article 3 and shall qualify any representations and warranties made by the
Company herein to the extent of the applicable disclosure: 


 


(a)            
Subsidiaries. Except as set forth on Section 3.1(a)
of the Disclosure Schedule, the Company has no direct or indirect Subsidiaries other than Corindus, Inc., a Delaware corporation
and wholly-owned subsidiary of the Company, and Corindus Security Corporation, a Delaware corporation and wholly-owned subsidiary
of the Company. The Company owns, directly or indirectly, all of the capital stock or comparable equity interests of each Subsidiary
free and clear of any and all Liens, and all the issued and outstanding shares of capital stock or comparable equity interest of
each Subsidiary are validly issued and are fully paid and non-assessable.


 






    7


    


    

 


(b)              
Organization and Qualification. The Company and each
Subsidiary is an entity duly incorporated, validly existing and in good standing under the laws of the jurisdiction of its incorporation,
with the requisite corporate power and authority to own or lease and use its properties and assets and to carry on its business
as currently conducted. The Company and its Subsidiaries are not in violation of any of the provisions of their certificate of
incorporation or bylaws. The Company and each of its Subsidiaries are duly qualified to conduct business and are in good standing
as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by
them makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would
not reasonably be expected to result in a Material Adverse Effect.


 


(c)               
Authorization; Enforcement; Validity. The Company
has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by each of the Transaction
Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery
of each of the Transaction Documents to which it is a party by the Company and the consummation by it of the transactions contemplated
hereby and thereby (including, but not limited to, the sale and delivery of the Shares) have been duly authorized by all necessary
corporate action on the part of the Company, and no further corporate action is required by the Company, its Board or its stockholders
in connection therewith other than in connection with the Required Approvals. Each of the Transaction
Documents to which it is a party has been (or upon delivery will have been) duly executed by the Company and is, or when delivered
in accordance with the terms hereof, will constitute the legal, valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies
or by other equitable principles of general application or insofar as indemnification and contribution provisions may be limited
by applicable law. There are no shareholder agreements, voting agreements, or other similar arrangements with respect to the Company’s
capital stock (i) to which the Company is a party or, (ii) to the Company’s Knowledge, between or among any of the Company’s
stockholders.


 


(d)              
Non Contravention. The execution, delivery and performance
by the Company of the Transaction Documents to which it is a party and the consummation by the Company of the transactions contemplated
hereby or thereby (including, without limitation, the issuance of the Shares) do not and will not (i)  violate any provisions
of the Company’s or its Subsidiaries’ certificate of incorporation or bylaws, (ii) constitute a default (or an event
that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company or give to others any rights of termination, amendment, acceleration or cancellation (with or without
notice, lapse of time or both) of, any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other
agreement, obligation, condition, covenant or instrument to which the Company or any of its Subsidiaries is a party or bound or
to which its or their property is subject or (iii) subject to the Required Approvals, conflict with, result in a violation
of, or imposition of any Lien, upon any property or assets of the Company pursuant to any law, rule, regulation, order, judgment,
injunction, decree or other restriction of any court, regulatory body, administrative agency, governmental authority, arbitrator
or other authority to which the Company or its Subsidiaries are subject (including federal and state securities laws and regulations
and the rules and regulations, assuming the correctness of the representations and warranties made by the Purchasers herein, of
any self-regulatory organization to which the Company or its securities are subject, including all applicable Trading Markets),
or by which any property or asset of the Company is bound or affected), except in the case of clause (ii) and clause (iii) such
as would not individually reasonably be expected to have a Material Adverse Effect.


 






    8


    


    

 


(e)               
Filings, Consents and Approvals. The Company is not
required to obtain any consent, waiver, approval, authorization or order of, qualification, designation, declaration, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or
other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents (including
the issuance of the Shares), other than (i) the filing with the Commission of one or more Registration Statements in accordance
with the requirements of the Registration Rights Agreement, (ii) filings required by applicable state securities laws after
the date hereof, (iii) the filing of a Notice of Sale of Securities on Form D with the Commission under Regulation D
of the Securities Act, (iv) the filing of any requisite notices and/or application(s) to the Principal Trading Market for
the issuance and sale of the Shares and the listing of the Shares for trading or quotation, as the case may be, thereon in the
time and manner required thereby (which will be made and approved prior to the Closing), (v) the filings required in accordance
with Section 4.6 of this Agreement and (vi) those that have been made or obtained prior to the date of this Agreement
satisfying the requirements thereof (collectively, the “Required Approvals”).


 


(f)                
Issuance of the Securities. The Shares have been
duly authorized and, when issued and paid for in accordance with the terms of the Transaction Documents, will be duly and validly
issued, fully paid and non-assessable and free and clear of all Liens, other than restrictions on transfer provided for in the
Transaction Documents or imposed by applicable securities laws, and shall not be subject to preemptive or similar rights. Assuming
the accuracy of the representations and warranties of the Purchasers in this Agreement, the Shares will be issued in compliance
with all applicable federal and state securities laws.


 


(g)              
Capitalization. The capitalization of the Company
is as described in the SEC Reports, except (i) as set forth on Section 3.1(g) of the Disclosure Schedule and (ii) for issuances
pursuant to this Agreement, stock option exercises, issuances pursuant to equity incentive plans or exercises of warrants. The
Company has not issued any capital stock since the date of its most recently filed SEC Report other than to reflect stock option
and warrant exercises that do not, individually or in the aggregate, have a material effect on the issued and outstanding capital
stock, options and other securities of the Company. No Person has any right of first refusal, preemptive right, right of participation,
or any similar right to participate in the transactions contemplated by the Transaction Documents, that have not been effectively
waived as of the Closing Date. Except as set forth on Section 3.1(g) of the Disclosure Schedule, there are no bonds, debentures,
notes or other indebtedness having general voting rights (or convertible into securities having such rights) (“Voting
Debt”) and no outstanding options, warrants, calls, subscriptions or other rights, agreements, arrangements or commitments
relating to the issued or unissued capital stock of the Company, obligating the Company to issue, transfer, sell, redeem, purchase,
repurchase or otherwise acquire or cause to be issued, transferred, sold, redeemed, purchased, repurchased or otherwise acquired
any capital stock or Voting Debt of, or other equity interests in, the Company or securities or rights convertible into or exchangeable
for such shares or equity interests or obligations of the Company to grant, extend or enter into any such option, warrant, call,
subscription or other right, arrangement or commitment. Except as set forth on Section 3.1(g) of the Disclosure Schedule,
the issuance and sale of the Shares will not obligate the Company to issue shares of Common Stock or other securities to any Person
(other than the Purchasers) and will not trigger any anti-dilution or price adjustment rights. All of the outstanding shares of
capital stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance in all material respects
with all applicable federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive
rights or similar rights to subscribe for or purchase securities which violation would have or would reasonably be expected to
result in a Material Adverse Effect. Except as set forth on Section 3.1(g) of the Disclosure Schedule, there are no registration
rights, stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock
to which the Company is a party or, to the Company’s Knowledge, between or among any of the Company’s stockholders.


 






    9


    


    

 


(h)              
SEC Reports. The Company has filed all reports, schedules,
forms, statements and other documents required to be filed by it under the Exchange Act, including pursuant to Section 13, 14(a)
and 15(d) thereof, for twelve (12) months preceding and including the Closing Date (the foregoing materials, including the exhibits
thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC Reports”
and together with this Agreement, including the Disclosure Schedule hereto, each as amended and supplemented to date, the “Disclosure
Materials”), on a timely basis or has received a valid extension of such time of filing and has filed any such SEC
Reports prior to the expiration of any such extension. As of their respective filing dates (or,
if amended prior to the date of this Agreement, when amended), all SEC Reports complied in all material respects with the requirements
of the Exchange Act and the rules and regulations of the Commission promulgated thereunder.  None of the SEC Reports
as of their respective dates contained any untrue statement of material fact or omitted to state a material fact required to be
stated therein or necessary to make the statements made therein, in light of the circumstances under which they were made, not
misleading. There is no transaction, arrangement, or other relationship between the Company (or any Subsidiary) and any unconsolidated
or other off balance sheet entity that is required to be disclosed by the Company in its Exchange Act filings that is not so disclosed.
Each franchise, contract or other document of a character required to be described in the SEC Reports or to be filed as an exhibit
to the SEC Reports under the Securities Act and the rules and regulations promulgated thereunder is so described or filed.


 


(i)                
Financial Statements. The consolidated financial
statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and
the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements
have been prepared in accordance with GAAP applied on a consistent basis during the periods involved, except as may be otherwise
specified in such financial statements or the notes thereto, and fairly present in all material respects the consolidated financial
position of the Company and its consolidated Subsidiaries taken as a whole as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, year-end audit adjustments.
As of the date hereof, there are no disagreements between the Company and its independent accounting firm on any matter of accounting
principles or practices, financial statement disclosure, or auditing scope or procedure relating to the Company’s fiscal
2018 audit or otherwise that, if not resolved to the satisfaction of the accounting firm, would result in the accounting firm referencing
such disagreement in its audit report for such fiscal year.


 


(j)                
Tax Matters. The Company and each of its Subsidiaries
(i) has prepared and filed all foreign, federal and state income and all other tax returns, reports and declarations required
to be filed prior to the date hereof by any jurisdiction to which it is subject, which are correct and complete in all material
respects for the periods to which such tax returns relate, (ii) has paid all taxes and other governmental assessments and
charges that are material in amount, shown or determined to be due prior to the date hereof on such returns, reports and declarations,
except those being contested in good faith, with respect to which adequate reserves have been set aside on the books of the Company
and (iii) has set aside on its books provisions reasonably adequate for the payment of all taxes for periods subsequent to
the periods to which such returns, reports or declarations apply, except where the failure to so file or pay or set aside provisions
for any such tax, assessment, charge or return would not reasonably be expected to have a Material Adverse Effect. There are in
effect no waivers of applicable statutes of limitations with respect to taxes for any year.


 






    10


    


    

 


(k)              
Material Changes. Since the date of the latest balance
sheet included in the financial statements contained within the SEC Reports, except as specifically disclosed in the SEC Reports
(i) there have been no events, occurrences or developments that have had or would reasonably be expected to have a Material
Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade
payables, accrued expenses and other liabilities incurred in the ordinary course of business consistent with past practice and
(B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or to be disclosed
in filings made with the Commission, (iii) the Company has not materially altered its method of accounting or the manner in
which it keeps its accounting books and records, (iv) the Company has not declared or made any dividend or distribution of
cash or other property to its stockholders, other than the quarterly dividends payable on the Company’s outstanding shares
of Series A Convertible Preferred Stock, $0.0001 par value per share, or purchased, redeemed or made any agreements to purchase
or redeem any shares of its capital stock (other than in connection with repurchases of unvested stock issued to employees of the
Company), (v) the Company has not issued any equity securities to any officer, director or Affiliate, except Common Stock
or other equity securities issued in the ordinary course pursuant to existing Company stock option or stock purchase plans or executive
and director corporate arrangements disclosed in the SEC Reports, (vi) there has not been any material change or amendment
to, or any waiver of any material right under, any Material Contract under which the Company or any of its assets is bound or subject,
and (vii) there have not been any changes in the authorized capital, assets, liabilities, financial condition, business or operations
of the Company from that reflected in the latest financial statements contained in the SEC Reports except changes in the ordinary
course of business which have not had or would not reasonably be expected to have, either individually or in the aggregate, a Material
Adverse Effect. Except as set forth on Section 3.1(k) of the Disclosure Schedule, neither
the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant to any law or statute relating to bankruptcy,
insolvency, reorganization, receivership, liquidation or winding up, nor does the Company or any Subsidiary have any knowledge
or reason to believe that any of their respective creditors intend to initiate involuntary bankruptcy proceedings or any actual
knowledge of any fact which would reasonably lead a creditor to do so.


 


(l)                
Environmental Matters. To the Company’s Knowledge,
the Company (i) is not in violation of any statute, rule, regulation, decision or order of any governmental agency or body
or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the
protection or restoration of the environment or human exposure to hazardous or toxic substances (collectively, “Environmental
Laws”), (ii) does not own or operate any real property contaminated with any substance that is in violation
of any Environmental Laws, (iii) is not liable for any off-site disposal or contamination pursuant to any Environmental Laws,
and (iv) is not subject to any claim relating to any Environmental Laws; which violation, contamination, liability or claim
has had or would have a Material Adverse Effect; and there is no pending or, to the Company’s Knowledge, threatened investigation
that might lead to such a claim. The Company and each of its Subsidiaries have received and are in compliance with all permits,
licenses or other approvals required of them under applicable Environmental Laws to conduct its business, except where such non-compliance
or failure to receive required permits, licenses or other approvals would not, individually or in the aggregate, have or reasonably
be expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has been named as a “potentially
responsible party” under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended.


 






    11


    


    

 


(m)            
Litigation. There is no Action which (i) adversely
affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Shares, or (ii) would
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Neither the Company nor any Subsidiary,
nor to the Company’s Knowledge any director or officer thereof, is or has been the subject of any Action involving a claim
of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been,
and to the Company’s Knowledge there is not pending or contemplated, any investigation by the Commission involving the Company
or, to the Company’s Knowledge, any current or former director or officer of the Company. The Commission has not issued
any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any of its Subsidiaries
under the Exchange Act or the Securities Act. There are no outstanding orders, judgments, injunctions, awards or decrees of any
court, arbitrator or governmental or regulatory body against the Company or, to the Company’s Knowledge, any executive officers
or directors of the Company in their capacities as such, which individually or in the aggregate, would reasonably be expected to
have a Material Adverse Effect.


 


(n)              
Employment Matters. No labor dispute exists or, to
the Company’s Knowledge, is imminent with respect to any of the employees of the Company or its Subsidiaries or any of its
principal suppliers or contractors which would have a Material Adverse Effect. None of the Company’s employees is a member
of a union that relates to such employee’s relationship with the Company, and the Company is not a party to a collective
bargaining agreement.


 


(o)              
Compliance. The Company and its Subsidiaries (i) are
not in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time
or both, would result in a default by the Company or its Subsidiaries), nor has the Company or any of its Subsidiaries received
written notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or
any other Material Contract (whether or not such default or violation has been waived), (ii) are not in violation of any order
of any court, arbitrator or governmental body having jurisdiction over the Company, its Subsidiaries or their properties or assets;
and (iii) are in compliance with, and have not receipted notice that they are in violation of, all statutes, laws, ordinances,
rules and regulations applicable to the Company and its Subsidiaries or to the Company Products (“Applicable Laws”),
including without limitation, all applicable rules and regulations of the Food and Drug Administration (the “FDA”),
except in each case as would not, individually or in the aggregate, have a Material Adverse Effect.


 


(p)              
Regulatory Permits. The Company and each of its Subsidiaries
possesses all licenses, certificates, approvals, permits and other authorizations and supplements or amendments thereto issued
by all applicable federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses (“Material
Permits”), including, without limitation, the FDA, such Material Permits are in
full force and effect, and (i) neither the Company nor any of its Subsidiaries has not received any notice of any adverse
finding, warning letter, assertion of noncompliance with, or adverse proceedings relating to the any such Material Permits; (ii) the
Company has no Knowledge of any facts or circumstances that the Company would reasonably expect to give rise to the revocation
or modification of any Material Permits; (iii) neither the Company nor any of its Subsidiaries has received written
notice of any ongoing claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any
governmental entity or third party alleging that any product manufactured by or on behalf of the Company or any of its Subsidiaries
or out-licensed by the Company or any of its Subsidiaries (a “Company Product”), operation or activity
related to a Company Product is in violation of any Applicable Laws or a Material Permit or has any knowledge that any such governmental
entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (iv) neither
the Company nor any of its Subsidiaries has received written notice that any governmental entity has taken, is taking or intends
to take action to limit, suspend, modify or revoke any Material Permit or has any knowledge that any such governmental entity has
threatened or is considering such action with respect to a Company Product; and (v) the Company and each of its Subsidiaries
have filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments as required by any Applicable Laws or Material Permits and that all such reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments were complete, correct and not misleading on
the date filed (or were corrected or supplemented by a subsequent submission). To the Company’s knowledge, neither the Company
nor any of its Subsidiaries, directors, officers, employees or agents, has made, or caused the making of, any false statements
on, or material omissions from, any other records or documentation prepared or maintained to comply with the requirements of the
FDA or any other governmental entity.


 






    12


    


    

 


(q)              
Title to Assets. The Company does not own any real
property. The Company and its Subsidiaries have good and marketable title to all tangible personal property owned by them which
is material to the business of the Company and its Subsidiaries, taken as a whole, in each case free and clear of all Liens except
such as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be
made of such property by the Company or its Subsidiaries and except for Liens for the payment of federal, state or other taxes
for which appropriate reserves have been made in accordance with GAAP and the payment of which is not delinquent or subject to
penalties. Any real property and facilities held under lease by the Company or its Subsidiaries are held by them under valid, subsisting
and enforceable leases with such exceptions as are not material and do not materially interfere with the use made of such property
and buildings by the Company or its Subsidiaries.


 


(r)               
Intellectual Property. The Company and its Subsidiaries
collectively own, possess, license or have other rights to use all material foreign and domestic patents, patent applications,
trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology,
know-how and other proprietary rights and processes necessary for the conduct of their businesses, taken as a whole, as now conducted
or as proposed in the SEC Reports to be conducted (collectively, the “Intellectual Property”). To
the Company’s Knowledge, (i) there are no rights of third parties to any Intellectual Property, other than as licensed
by the Company; (ii) the Company’s or its Subsidiaries’ use of any such Intellectual Property in the conduct of its
business as presently conducted does not infringe upon the rights of any third parties; (ii) there is no infringement by third
parties of any such Intellectual Property; (iii) there is no pending or threatened Action challenging the Company’s
rights in or to or scope of any such Intellectual Property; (iv) there is no pending or threatened Action challenging the
validity or scope of any such Intellectual Property; and (v) there is no pending or threatened Action that the Company infringes
or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of others. The Company is not
aware of any facts required to be disclosed to the U.S. Patent and Trademark Office which have not been disclosed to the U.S. Patent
and Trademark Office and which would preclude the grant of a patent in connection with any patent application of the Intellectual
Property or could form the basis of a finding of invalidity with respect to any issued patents of the Intellectual Property. 
The Company and its Subsidiaries collectively have taken reasonable security measures to protect the secrecy, confidentiality and
value of all of the Intellectual Property, except where the failure to do so would not, individually or in the aggregate, have
or reasonably be expected to have a Material Adverse Effect.


 


(s)               
Insurance. The Company and each of its Subsidiaries
is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are reasonable
and customary in the business in which it is engaged; all policies of insurance and fidelity or surety bonds insuring the Company
and each of its Subsidiaries or their respective businesses, assets, employees, officers and directors are in full force and effect;
the Company and each of its Subsidiaries is in compliance with the terms of such policies and instruments in all material respects;
there are no claims by the Company or any of its Subsidiaries under any such policy or instrument as to which any insurance company
is denying liability or defending under a reservation of rights clause; and neither the Company nor any of its Subsidiaries has
been refused any insurance coverage sought or applied for. The Company has not received any notice of cancellation of any such
insurance, nor does the Company have any Knowledge that it will be unable to renew its existing insurance coverage for the Company
as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business
without a significant increase in cost.


 






    13


    


    

 


(t)                
Transactions with Affiliates and Employees. None
of the officers or directors of the Company and, to the Company’s Knowledge, none of the employees of the Company, is presently
a party to any transaction with the Company or to a transaction presently contemplated by the Company (other than for services
as employees, officers and directors) that would be required to be disclosed by the Company pursuant to Item 404 of Regulation S-K
promulgated under the Securities Act, except as contemplated by the Transaction Documents or set forth in the SEC Reports.


 


(u)              
Internal Accounting Controls. The Company maintains
a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance
with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of
financial statements in conformity with GAAP and to maintain asset and liability accountability, (iii) access to assets or incurrence
of liabilities is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded
accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate
action is taken with respect to any differences. The Company’s internal controls over financial reporting (as defined in
Rule 13a-15(f) under the Exchange Act) are effective to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles
and the Company is not aware of any material weakness in its internal controls over financial reporting.  


 


(v)              
Sarbanes-Oxley. Except as disclosed in the SEC Reports,
the Company is in compliance in all material respects with all of the provisions of the Sarbanes-Oxley Act of 2002 which are applicable
to it. The Company has established disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e)
under the Exchange Act) for the Company and designed such disclosure controls and procedures to ensure that information required
to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and
reported, within the time periods specified in the Commission’s rules and forms. The Company’s certifying officers
have evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered
by the Company’s most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”).
The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers
about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date) and such
disclosure controls and procedures are effective. Since the Evaluation Date, there have been no changes in the Company’s
internal control over financial reporting (as such term is defined in the Exchange Act) that have materially affected, or are reasonably
likely to materially affect, the Company’s internal control over financial reporting. 


 


(w)             
Certain Fees. No person or entity will have, as a
result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company or a
Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by
or on behalf of the Company.


 


(x)              
Private Placement. Assuming the accuracy of the Purchasers’
representations and warranties set forth in Section 3.2 of this Agreement (without giving effect to any materiality
qualifiers therein) and the accuracy of the information disclosed by each Purchaser in the Accredited Investor Questionnaire delivered
pursuant to Section 2.2(b)(iv) and Section 5.3(d), no registration under the Securities Act is required
for the offer and sale of the Shares by the Company to the Purchasers under the Transaction Documents.


 






    14


    


    

 


(y)              
No General Solicitation. Neither the Company nor
any Person acting on its behalf has conducted any “general solicitation” or “general advertising” (as those
terms are used in Regulation D) in connection with the offer or sale of any of the Shares.


 


(z)               
No Integrated Offering. Assuming the accuracy of
the Purchasers’ representations and warranties set forth in Section 3.2 (without giving effect to any materiality
qualifiers therein), neither the Company nor any Person acting on its behalf has, directly or indirectly, at any time within the
past six (6) months, made any offers or sales of any Company security or solicited any offers to buy any security under circumstances
that would (i) eliminate the availability of the exemption from registration under Section 4(a)(2) or Regulation D under
the Securities Act in connection with the offer and sale by the Company of the Shares as contemplated hereby or (ii) cause
the Offering of the Shares pursuant to the Transaction Documents to be integrated with prior offerings by the Company for purposes
of any applicable law, regulation or shareholder approval provisions, including, without limitation, under the rules and regulations
of any Trading Market on which any of the securities of the Company are listed or designated.


 


(aa)           
Registration Rights. Other than the Purchasers pursuant
to the Registration Rights Agreement or as disclosed in Section 3.1(aa) of the Disclosure Schedule, no Person has any right
to cause the Company to effect the registration under the Securities Act of any securities of the Company.


 


(bb)          
Listing and Maintenance Requirements. The Company’s
Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and the Company has taken no action designed to terminate
the registration of the Common Stock under the Exchange Act, nor has the Company received any notification that the Commission
is contemplating terminating such registration. There are no proceedings pending or, to the Company’s Knowledge, threatened
against the Company relating to the continued listing of the Company’s common stock on the Principal Trading Market and the
Company has not, in the 12 months preceding the date hereof, received written notice from any Trading Market on which the Common
Stock is listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such
Trading Market. The Company is in compliance with all listing and maintenance requirements of the Principal Trading Market on the
date hereof and the issuance of the Shares will not violate any such listing or maintenance requirements.


 


(cc)           
Application of Takeover Protections; Rights Agreements.
The Company and its board of directors have taken all necessary action, if any, in order to render inapplicable any control share
acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover
provision under the Company’s charter documents or the laws of the State of Delaware that is or could reasonably be expected
to become applicable to any of the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising
their rights under the Transaction Documents, including, without limitation, the Company’s issuance of the Shares and the
Purchasers’ ownership of the Shares. The Company has not adopted a stockholder rights plan or similar arrangement relating
to accumulations of beneficial ownership of Common Stock or a change in control of the Company.


 


(dd)          
Off Balance Sheet Arrangements. There is no transaction,
arrangement, or other relationship between the Company and an unconsolidated or other off balance sheet entity that is required
to be disclosed by the Company in its SEC Reports (including, for purposes hereof, any that are required to be disclosed in a Form
10) and is not so disclosed or that otherwise would have a Material Adverse Effect.


 






    15


    


    

 


(ee)           Foreign
Corrupt Practices. Neither the Company nor any of its Subsidiaries, nor to the Company’s
Knowledge, any agent or other person acting on behalf of the Company or its Subsidiaries, has: (i) directly or indirectly, used
any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political
activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic
political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made
by any person acting on its behalf of which the Company is aware) which is in violation of law or (iv) taken any action, directly
or indirectly, that would result in a violation by the Company or such persons of the Foreign Corrupt Practices Act of 1977, as
amended, and the rules and regulations thereunder.


  


(ff)              
Money Laundering Laws. The operations of the Company
and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting
requirements and the money laundering statutes and the rules and regulations thereunder and any related or similar rules,
regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering
Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the Knowledge
of the Company, threatened.


 


(gg)          
OFAC. Neither the Company nor any of its Subsidiaries
nor, to the Knowledge of the Company, any director, officer, agent or employee of the Company or any of its Subsidiaries (i) is
currently subject to any sanctions administered or imposed by the United States (including any administered or enforced by the
Office of Foreign Assets Control of the U.S. Treasury Department, the U.S. Department of State, or the Bureau of Industry and Security
of the U.S. Department of Commerce), the United Nations Security Council, the European Union, or the United Kingdom (including
sanctions administered or controlled by Her Majesty’s Treasury) (collectively, “Sanctions” and
such persons, “Sanction Persons”) or (ii) will, directly or indirectly, use the proceeds of this
offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person
in any manner that will result in a violation of any economic Sanctions by, or could result in the imposition of Sanctions against,
any person (including any person participating in the offering, whether as underwriter, advisor, investor or otherwise). Neither
the Company nor any of its Subsidiaries nor, to the Knowledge of the Company, any director, officer, agent, or employee of the
Company or any of its Subsidiaries, is a person that is, or is 50% or more owned or otherwise controlled by a person that is: (i) the
subject of any Sanctions; or (ii) located, organized or resident in a country or territory that is, or whose government is,
the subject of Sanctions that broadly prohibit dealings with that country or territory (collectively, “Sanctioned Countries”
and each, a “Sanctioned Country”). To the Knowledge of the Company, neither the Company nor any of its
Subsidiaries has engaged in any dealings or transactions with or for the benefit of a Sanctioned Person, or with or in a Sanctioned
Country, in the preceding three years, nor does the Company or its Subsidiaries have any plans to increase their respective dealings
or transactions with Sanctioned Persons, or with or in Sanctioned Countries.


 


(hh)          
Transfer Taxes.  There are no transfer taxes
or other similar fees or charges under Federal law or the laws of any state, or any political subdivision thereof, required to
be paid in connection with the execution and delivery of this Agreement or the issuance by the Company or sale by the Company of
the Shares.


 


(ii)              
Investment Company.  The Company is not and,
after giving effect to the offering and sale of the Shares, will not be an “investment company” as defined in the Investment
Company Act of 1940, as amended.


 






    16


    


    

 


(jj)             
Price of Common Stock.  The Company has not,
and to the Company’s Knowledge no one acting on its behalf has, taken, directly or indirectly, any action designed to cause
or result in, or that has constituted or that might reasonably be expected to constitute the stabilization or manipulation of the
price of any securities of the Company to facilitate the sale or resale of the Shares.


 


(kk)          ERISA. 
None of the following events has occurred or exists: (i) a failure to fulfill the obligations, if any, under the minimum
funding standards of Section 302 of the United States Employee Retirement Income Security Act of 1974, as amended (“ERISA”),
and the regulations and published interpretations thereunder with respect to a Plan that is required to be funded, determined
without regard to any waiver of such obligations or extension of any amortization period; (ii) an audit or investigation
by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other federal or
state governmental agency or any foreign regulatory agency with respect to the employment or compensation of employees by any
of the Company that would reasonably be expected to have a Material Adverse Effect; (iii) any breach of any contractual obligation,
or any violation of law or applicable qualification standards, with respect to the employment or compensation of employees by
the Company that would reasonably be expected to have a Material Adverse Effect. None of the following events has occurred or
is reasonably likely to occur: (i) a material increase in the aggregate amount of contributions required to be made to all
Plans in the current fiscal year of the Company compared to the amount of such contributions made in the most recently completed
fiscal year of the Company; (ii) a material increase in the “accumulated post-retirement benefit obligations”
(within the meaning of Statement of Financial Accounting Standards 106) of the Company compared to the amount of such obligations
in the most recently completed fiscal year of the Company; (iii) any event or condition giving rise to a liability under
Title IV of ERISA that would reasonably be expected to have a Material Adverse Effect; or (iv) the filing of a claim by one
or more employees or former employees of the Company related to their employment that would reasonably be expected to have a Material
Adverse Effect. For purposes of this paragraph, the term “Plan” means a plan (within the meaning of Section 3(3) of
ERISA) subject to Title IV of ERISA with respect to which the Company may have any liability.


 


(ll)              
No “Bad Actor” Disqualification. 
To the Company’s Knowledge, no Covered Person is subject to any of the “bad actor” disqualifications described
in Rule 506(d)(1)(i) to (viii) under the Securities Act (“Disqualification Events”), except
for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company has complied,
to the extent applicable, with any disclosure obligations under Rule 506(e) under the Securities Act. “Covered
Persons” are those persons specified in Rule 506(d)(1) under the Securities Act, including the Company;
any predecessor or affiliate of the Company; any director, executive officer, other officer participating in the offering, general
partner or managing member of the Company; any beneficial owner of 20% or more of the Company’s outstanding voting equity
securities, calculated on the basis of voting power; any promoter (as defined in Rule 405 under the Securities Act) connected
with the Company in any capacity at the time of the sale of the Shares; and any person that has been or will be paid (directly
or indirectly) remuneration for solicitation of purchasers in connection with the sale of the Shares (a “Solicitor”),
any general partner or managing member of any Solicitor, and any director, executive officer or other officer participating in
the offering of any Solicitor or general partner or managing member of any Solicitor.


 


(mm)      
Registration Eligibility.  To the Knowledge
of the Company, the Company is eligible to register the resale of the Shares by the Purchasers using Form S-3 promulgated
under the Securities Act.


 






    17


    


    

 


(nn)          
Disclosure.  The Company understands and confirms
that the Purchasers will rely on the foregoing representations in effecting transactions in securities of the Company. The
Disclosure Materials, and all due diligence materials regarding the Company, its business and the transactions contemplated hereby
that are not projections or forward-looking statements, furnished by or on behalf of the Company to any Purchaser in connection
with such Purchaser’s evaluation of the Company are, when taken together with the Disclosure Materials, true and correct
in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. All projections
and forward-looking statements regarding the Company and its business, furnished by or on behalf of the Company to any Purchaser
in connection with such Purchaser’s evaluation of the Company, were made on a good faith, reasonable basis by Company management.


 


3.2             
  Representations and Warranties of the Purchasers.
Each Purchaser hereby, for itself and for no other Purchaser, represents and warrants as of the date hereof and as of the Closing
Date to the Company as follows: 


 


(a)              
Organization; Authority. Such Purchaser is an entity
duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite
corporate, partnership, limited liability company or other similar power and authority to enter into and to consummate the transactions
contemplated by the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder.
The execution, delivery and performance by such Purchaser of the transactions contemplated by this Agreement have been duly authorized
by all necessary corporate or, if such Purchaser is not a corporation, such partnership, limited liability company or other applicable
like action, on the part of such Purchaser. Each Transaction Document to which it is a party has been (or,
upon delivery, will have been) duly executed by such Purchaser, and when delivered by such Purchaser in accordance with
the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance
with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by
other equitable principles of general application or insofar as indemnification and contribution provisions may be limited by applicable
law.


 


(b)              
Non Contravention. The execution, delivery and performance
by such Purchaser of the Transaction Documents to which it is a party and the consummation by such Purchaser of the transactions
contemplated hereby and thereby will not (i) result in a violation of the organizational documents of such Purchaser, (ii) constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Purchaser is a party
or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities
laws) applicable to such Purchaser, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults,
rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect
on the ability of such Purchaser to perform its obligations hereunder.


 


(c)               
Investment Intent. Such Purchaser understands that
the Shares are “restricted securities” and have not been registered under the Securities Act or any applicable state
securities law and is acquiring the Shares as principal for its own account and not with a view to, or for distributing or reselling
such Shares or any part thereof in violation of the Securities Act or any applicable state securities laws. Such Purchaser is acquiring
the Shares hereunder in the ordinary course of its business. Such Purchaser does not presently have any agreement, plan or understanding,
directly or indirectly, with any Person to distribute or effect any distribution of any of the Shares (or any securities which
are derivatives thereof) to or through any person or entity; such Purchaser is not a registered broker-dealer under Section 15
of the Exchange Act or an entity engaged in a business that would require it to be so registered as a broker-dealer.


 






    18


    


    

 


(d)              
Purchaser Status. At the time such Purchaser was
offered the Shares, it was, and at the date hereof it is, an “accredited investor” as defined in Rule 501(a) under
the Securities Act, for the reason(s) specified on the Accredited Investor Questionnaire attached hereto as completed by such Purchaser,
and such Purchaser shall submit to the Company such further assurances of such status as may be reasonably requested by the Company.


 


(e)               
General Solicitation. Such Purchaser is not purchasing
the Shares as a result of any advertisement, article, notice or other communication regarding the Shares published in any newspaper,
magazine or similar media or broadcast over television or radio or presented at any seminar or any other general advertisement.


 


(f)                
Experience of Such Purchaser. Such Purchaser, either
alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters
so as to be capable of evaluating the merits and risks of the prospective investment in the Shares, and has so evaluated the merits
and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Shares and, at the present
time, is able to afford a complete loss of such investment.


 


(g)              
Access to Information. Such Purchaser acknowledges
that it has had the opportunity to review the Disclosure Materials and has been afforded (i) the opportunity to ask such questions
as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions
of the Offering of the Shares and the merits and risks of investing in the Shares; (ii) access to information about the Company
and its respective financial condition, results of operations, business, properties, management and prospects sufficient to enable
it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses
or can acquire without unreasonable effort or expense that is necessary to make an informed investment
decision with respect to the investment. Neither such inquiries nor any other investigation conducted by or on behalf of such
Purchaser or its representatives or counsel shall modify, amend or affect such Purchaser’s
right to rely on the truth, accuracy and completeness of the Disclosure Materials and the Company’s representations and warranties
contained in the Transaction Documents (as qualified by the Disclosure Materials). Such Purchaser has sought such accounting, legal
and tax advice as it has considered necessary to make an informed decision with respect to its acquisition of the Shares.


 


(h)              
Certain Trading Activities. Other than with respect
to the transactions contemplated herein, since the time such Purchaser was first contacted by the Company or any other Person regarding
the transactions contemplated hereby, neither such Purchaser nor any Affiliate of such Purchaser (including, for purposes of this
Section 3.2(h), any limited partner of such Purchaser) has, directly or indirectly, nor has any Person acting on behalf
of or pursuant to any understanding with such Purchaser or an Affiliate of such Purchaser, effected or agreed to effect any transactions
in the securities of the Company (including, without limitation, any Short Sales involving the Company’s securities). Neither
such Purchaser nor any Affiliate of such Purchaser holds any short position in the Company’s securities. Other than to other
Persons party to this Agreement or to employees or advisors of such Purchaser, such Purchaser has maintained the confidentiality
of all disclosures made to it in connection with the transactions contemplated hereby (including the existence and terms of such
transactions). 


 


(i)                
Brokers and Finders. No Person will have, as a result
of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company or any Purchaser
for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf
of such Purchaser.


 






    19


    


    

 


(j)                
Independent Investment Decision. Such Purchaser has
independently evaluated the merits of its decision to purchase Shares pursuant to the Transaction Documents, and such Purchaser
confirms that it has not relied on the advice of any other Person’s business and/or legal counsel in making such decision.
Such Purchaser understands that nothing in this Agreement or any other materials presented by or on behalf of the Company to the
Purchaser in connection with the purchase of the Shares constitutes legal, tax or investment advice. Such Purchaser has consulted
such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its
purchase of the Shares.


  


(k)              
Reliance on Exemptions. Such Purchaser understands
that the Shares are being offered and sold to it in reliance on specific exemptions from the registration requirements of United
States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and such Purchaser’s
compliance with, the representations, warranties, agreements, acknowledgements and understandings of
such Purchaser set forth herein in order to determine the availability of such exemptions and
the eligibility of such Purchaser to acquire the Shares.


 


(l)                
No Governmental Review. Such Purchaser understands
that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation
or endorsement of the Shares or the fairness or suitability of the investment in the Shares nor have such authorities passed upon
or endorsed the merits of the Offering of the Shares.


 


(m)            
Regulation M. Such Purchaser is aware that the
anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of Common Stock and other activities with
respect to the Common Stock by the Purchasers.


 


(n)              
Residency. Such Purchaser’s principal executive
offices are in the jurisdiction set forth immediately below such Purchaser’s name on the signature page attached hereto.


 


 (q)       Prohibited
Purchaser. Such Purchaser represents that neither it nor, to its knowledge, any person or entity controlling, controlled by
or under common control with it, nor any person having a beneficial interest in it, nor any person on whose behalf the Purchaser
is acting: (i) is a person listed in the Annex to Executive Order No. 13224 (2001) issued by the President of the United States
(Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism);
(ii) is named on the List of Specially Designated Nationals and Blocked Persons maintained by the U.S. Office of Foreign Assets
Control; (iii) is a non-U.S. shell bank or is providing banking services indirectly to a non-U.S. shell bank; (iv) is a senior
non-U.S. political figure or an immediate family member or close associate of such figure; or (v) is otherwise prohibited from
investing in the Company pursuant to applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations,
rules or orders (categories (i) through (v), each a “Prohibited Purchaser”). The Purchaser agrees to
provide the Company, promptly upon request, all information that the Company reasonably deems necessary or appropriate to comply
with applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations, rules and orders. The Purchaser
consents to the disclosure to U.S. regulators and law enforcement authorities by the Company and its Affiliates and agents of such
information about the Purchaser as the Company reasonably deems necessary or appropriate to comply with applicable U.S. antimony
laundering, anti-terrorist and asset control laws, regulations, rules and orders. If the Purchaser is a financial institution that
is subject to the USA Patriot Act, the Purchaser represents that it has met all of its obligations under the USA Patriot Act. The
Purchaser acknowledges that if, following its investment in the Company, the Company reasonably believes that the Purchaser is
a Prohibited Purchaser, the Company has the right or may be obligated to prohibit additional investments, segregate the assets
constituting the investment in accordance with applicable regulations or immediately require the Purchaser to transfer the Shares.
The Purchaser further acknowledges that the Purchaser will have no claim against the Company or any of its Affiliates or agents
for any form of damages as a result of any of the foregoing actions.


 






    20


    


    

 


The Company and each
of the Purchasers acknowledge and agree that no party to this Agreement has made or makes any representations or warranties with
respect to the transactions contemplated hereby other than those specifically set forth in this Article III and the Transaction
Documents and that, except as otherwise provided herein, neither the Company nor any Purchaser has relied on the accuracy or completeness
of any information not contained in the Transaction Documents.


 


Article
4

OTHER AGREEMENTS OF THE PARTIES


 


4.1             
 Transfer Restrictions.


 


(a)              
Compliance with Laws. Notwithstanding any other provision
of the Transaction Documents, each Purchaser covenants that the Shares may be disposed of only pursuant to an effective registration
statement under, and in compliance with the requirements of, the Securities Act, or pursuant to an available exemption from, or
in a transaction not subject to, the registration requirements of the Securities Act, and in compliance with any applicable state
and federal securities laws. In connection with any transfer of the Shares other than (i) pursuant to an effective registration
statement, (ii) to the Company, (iii) pursuant to Rule 144, or (iv) in connection with a bona fide pledge,
the Company may require the transferor thereof to provide to the Company an opinion of counsel (which, for the avoidance of doubt,
may include in-house legal counsel to the Purchaser), the form and substance of which opinion shall be reasonably satisfactory
to the Company, to the effect that such transfer does not require registration of such transferred Shares under the Securities
Act, and, as a condition of such transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement
and shall have the rights of a Purchaser under this Agreement and the Registration Rights Agreement.


 


(b)              
Lock-Up Period; Certain Dispositions. Each Purchaser
shall not, directly or indirectly, during the 6-month period immediately following the Closing Date (the “Lock-Up
Period”), (A) sell, offer to sell, solicit offers to buy, dispose of, loan, pledge or grant any right with respect
to (collectively, a “Disposition”) the Shares or (B) engage in any Short Sales or hedging
transactions involving the Company’s securities. In addition, each Purchaser agrees that for so long as it owns any Common
Stock, it will not enter into any Short Sale of Shares executed at a time when such Purchaser has no equivalent offsetting long
position in the Common Stock. For purposes of determining whether such Purchaser has an equivalent offsetting long position in
the Common Stock, shares that such Purchaser is entitled to receive within sixty (60) days (whether pursuant to contract or
upon conversion or exercise of convertible securities) will be included as if held long by such Purchaser. Each Purchaser covenants
that neither it nor any Person acting on its behalf or pursuant to any understanding with it will engage in any transactions in
the Company’s securities (including, without limitation, any Short Sales involving the Company’s securities) during
the period from the date hereof until the earlier of such time as (i) the expiration of the Lock-Up Period or (ii) this
Agreement is terminated in full pursuant to Section 6.16. Each Purchaser understands and acknowledges, severally and
not jointly with any other Purchaser, that the Commission currently takes the position that covering a short position established
prior to effectiveness of a resale registration statement with shares included in such registration statement would be a violation
of Section 5 of the Securities Act, as set forth in Division of Corporation Financing Compliance and Disclosure Interpretation
239.10 regarding short selling.


 






    21


    


    

 


(c)               
Legends. Certificates evidencing the Shares shall
bear any legend as required by the “Blue Sky” laws of any state and restrictive legends in substantially the following
form until such time as they are not required under Section 4.1(d) (and a stock transfer order may be placed against
transfer of the Shares): 


 


THESE SECURITIES HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE
SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS
SOLD PURSUANT TO RULE 144 UNDER SAID ACT.


 


THE SHARES ARE SUBJECT
TO A SIX (6)-MONTH LOCK-UP PERIOD, AS SET FORTH IN A SECURITIES PURCHASE AGREEMENT AMONG THE COMPANY AND THE ORIGINAL HOLDER OF
THESE SHARES, COPIES OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY.


 


In addition, if the
Company reasonably determines that any Purchaser is an Affiliate of the Company, the certificate evidencing the Shares issued to
such Purchaser shall bear a customary “Affiliates” legend.


 


(d)              
Removal of Legends. Subject to the Company’s
right to request an opinion of counsel as set forth in Section 4.1(a), the legends set forth in Section 4.1(c)
above shall be removable and the Company shall remove such legends or any other legends and issue and cause to be issued to such
holder by electronic delivery at the applicable balance account at The Depository Trust Company (“DTC”)
evidence of a book entry position, free and clear of all restrictive and other legends or instructions as provided in this Section 4.1(d),
if, at any time following the expiration of the Lock-up Period, (i) such Shares are registered for resale under the Securities
Act and the Purchaser is selling pursuant to the effective registration statement registering the Shares for resale (provided that,
the Purchaser agrees to only sell such Shares during such time that such registration statement is effective and not withdrawn
or suspended, and only as permitted by such registration statement), or (ii) such Shares are sold or transferred in compliance
with Rule 144 (if the transferor is not an Affiliate of the Company), including without limitation in compliance with the current
public information requirements of Rule 144 if applicable to the Company at the time of such sale or transfer, and the holder and
its broker have delivered customary documents reasonably requested by the Transfer Agent and/or Company Counsel in connection with
such sale or transfer. Any fees (with respect to the Transfer Agent, Company Counsel or otherwise) associated with the removal
of such legend shall be borne by the Company. Following the Effective Date (as defined in the Registration Rights Agreement), or
at such other time as a legend is no longer required for certain Shares, the Company will no later than three (3) Trading
Days following the delivery by a Purchaser to the Company or the Transfer Agent (with concurrent notice and delivery of copies
to the Company) of a legended certificate representing such Shares (endorsed or with stock powers attached, signatures guaranteed,
and otherwise in form necessary to affect the reissuance and/or transfer, and together with such other customary documents as the
Transfer Agent and/or Company Counsel shall reasonably request), deliver or cause to be delivered to the transferee of such Purchaser
or such Purchaser, as applicable, a certificate representing such Shares that is free from all restrictive and other legends. Certificates
for Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchasers, as applicable, by
crediting the account of the transferee’s or Purchaser’s prime broker with DTC.


 






    22


    


    

 


(e)               
Irrevocable Transfer Agent Instructions. The Company
shall issue irrevocable instructions to its Transfer Agent, and any subsequent Transfer Agent, in the form of Exhibit E
attached hereto (the “Irrevocable Transfer Agent Instructions”). The Company represents and warrants
that no instruction other than the Irrevocable Transfer Agent Instructions or instructions consistent therewith or otherwise contemplated
hereby or thereby or by the other Transaction Documents or such other documents as the Transfer Agent may request in connection
with any such instructions will be given by the Company to its Transfer Agent in connection with this Agreement, and that the Shares
shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in and subject to
the terms of this Agreement, the other Transaction Documents and applicable law. 


 


(f)                
Acknowledgement. Each Purchaser hereunder acknowledges
its primary responsibilities under the Securities Act and accordingly will not sell or otherwise transfer the Shares or any interest
therein without complying with the requirements of the Securities Act. While the Registration Statement remains effective, each
Purchaser hereunder may sell the Shares in accordance with the plan of distribution contained in the Registration Statement and,
if it does so, it will comply therewith and with the related prospectus delivery requirements unless an exemption therefrom is
available. Each Purchaser, severally and not jointly with the other Purchasers, agrees that if it is notified
by the Company in writing at any time that the Registration Statement registering the resale of the Shares is not effective or
that the prospectus included in such Registration Statement no longer complies with the requirements of Section 10 of the
Securities Act, such Purchaser will refrain from selling such Shares until such time as such Purchaser is notified by the Company
that such Registration Statement is effective or such prospectus is compliant with Section 10 of the Securities Act, unless
such Purchaser is able to, and does, sell such Shares pursuant to an available exemption from
the registration requirements of Section 5 of the Securities Act. Each Purchaser acknowledges that the delivery of the Irrevocable
Transfer Agent Instructions and any removal of any legends from certificates representing the Shares as set forth in this Section 4.1
is predicated on the Company’s reliance upon the Purchaser’s acknowledgement in this Section 4.1(f).


 


4.2             
 Acknowledgment of Dilution. The Company acknowledges
that the issuance of the Shares may result in dilution of the outstanding shares of Common Stock. The Company further acknowledges
that its obligations under the Transaction Documents, including without limitation its obligation to issue the Shares pursuant
to the Transaction Documents, are, subject to the terms and conditions expressly set forth in this Agreement, unconditional and
absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution
or any claim the Company may have against any Purchaser and regardless of the dilutive effect that such issuance may have on the
ownership of the other stockholders of the Company.


 


4.3             
  Form D and Blue Sky. The Company agrees to timely
file a Form D with respect to the Shares as required under Regulation D and to provide a copy thereof to each Purchaser
who requests a copy in writing promptly after such filing. The Company shall take such action as the Company shall reasonably determine
is necessary in order to qualify the Shares for sale to the Purchasers at the Closing pursuant to this Agreement under applicable
securities or “Blue Sky” laws of the states of the United States (or to obtain an exemption from such qualification),
which, subject to the accuracy of the Company’s and the Purchaser’s representations and warranties set forth herein,
shall consist of the submission of all filings and reports relating to the offer and sale of the Shares pursuant to Rule 506 of
Regulation D required under applicable securities or “Blue Sky” laws of the states of the United States following the
Closing Date, and shall provide evidence of any such action so taken to the Purchasers who request in writing such evidence.


 






    23


    


    

 


4.4             
  No Integration. The Company shall not, and shall
use its commercially reasonable efforts to ensure that the Affiliates of the Company shall not, sell, offer for sale or solicit
offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that will
be integrated with the offer or sale of the Shares in a manner that would require the registration under the Securities Act of
the sale of the Shares to the Purchasers, or that will be integrated with the offer or sale of the Shares for purposes of the rules
and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction.


 


4.5             
  Indemnification.


 


(a)               
Indemnification of the Purchasers. In addition to
the indemnity provided in the Registration Rights Agreement, subject to this Section 4.8, the Company will indemnify
and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons
with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each
Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange
Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling Person
(each, a “Purchaser Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies,
damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’
fees and costs of investigation that any such Purchaser Party may suffer or incur, as a result of or relating to: (1) third party
claims against such Purchaser relating to any breach of any of the representations, warranties, covenants or agreements made by
the Company in this Agreement or in the other Transaction Documents, and (2) third party claims against a Purchaser or any of its
Affiliates, in any capacity, by any Person who is not an Affiliate, limited partner, or other investor of such Purchaser, with
respect to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of such
Purchaser’s representations, warranties or covenants under the Transaction Documents or any conduct by such Purchaser which
constitutes fraud, gross negligence, willful misconduct or malfeasance). The Company will not be liable to any Purchaser Party
under this Agreement to the extent, but only to the extent that a loss, claim, damage or liability is attributable to (i) the failure
of such Purchaser Party to comply with the covenants and agreements contained in Section 4.8 below respecting sale of the
Shares, (ii) the inaccuracy of any representations made by such Purchaser Party herein, or (iii) information regarding such Purchaser
Party furnished in such Purchaser Party’s Accredited Investor Questionnaire to the Company by such Purchaser Party.


 


(b)              
Conduct of Indemnification Proceedings. Promptly
after receipt by any Person (the “Indemnified Person”) of notice of any demand, claim or circumstances
which would or might give rise to a claim or the commencement of any action, proceeding or investigation in respect of which indemnity
may be sought pursuant to Section 4.8(a), such Indemnified Person shall promptly notify the Company in writing and the Company
shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to such Indemnified
Person and the assumption of the payment of all fees and expenses; provided, however, that the failure of any Indemnified
Person to so notify the Company shall not relieve the Company of its obligations hereunder except to the extent that the Company
is actually and materially prejudiced by such failure to notify. In any such proceeding, any Indemnified Person shall have the
right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless:
(i) the Company and the Indemnified Person shall have mutually agreed to the retention of such counsel; (ii) the Company shall
have failed promptly to assume the defense of such proceeding or the Company does not, upon assuming the defense of such proceeding,
conduct the defense of such claim actively and diligently; or (iii) the named parties to any such proceeding (including any
impleaded parties) include both such Indemnified Person and the Company, and such Indemnified Person shall have been advised by
counsel that a conflict of interest exists if the same counsel were to represent such Indemnified Person and the Company; (iv)
the claim is based upon any proceeding, indictment, allegation or investigation of a criminal nature; or (v) the claim seeks an
injunction or non-monetary or equitable relief against the Indemnified Person, other than any such claim that is incidental to
the primary claim or claims and not material (in the case of clauses (ii)-(v), if such Indemnified Party notifies the Company in
writing that it elects to employ separate counsel at the expense of the Company, the Company shall not have the right to assume
the defense thereof and such counsel shall be at the expense of the Company). The Company shall not be liable for any settlement
of any proceeding effected without its written consent, which consent shall not be unreasonably withheld, delayed or conditioned.
Without the prior written consent of the Indemnified Person, which consent shall not be unreasonably withheld, delayed or conditioned,
the Company shall not effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person
is a party, unless such settlement includes an unconditional release of such Indemnified Person from
all liability arising out of such Proceeding and such settlement does not require any Indemnified Person to perform any covenant
or refrain from engaging in any activity or include any non-monetary limitation on the actions of any Indemnified Person or any
of its Affiliates or any admission of fault, violation, culpability, malfeasance or nonfeasance by, or on behalf of, or liability
on behalf of, any such Indemnified Person.


 






    24


    


    

 


4.6    
      Listing of Securities. In the time and manner required
by the Principal Trading Market, the Company shall prepare and file with such Trading Market any additional shares listing application
that may be required by such Trading Market covering all of the Shares and shall use its commercially reasonable efforts to take
all steps necessary to maintain, so long as any other shares of Common Stock shall be so listed, such listing.


 


4.7    
           Securities Laws Disclosure; Publicity. On or before
9:00 a.m., New York City time, on the Business Day immediately following the date hereof, the Company shall issue a press release
(the “Press Release”) reasonably acceptable to the Purchasers disclosing all material terms of the
transactions contemplated hereby. On or before 5:30 p.m., New York City time, on the fourth Trading Day immediately following the
execution of this Agreement, the Company will file a Current Report on Form 8-K with the Commission describing the terms of the
Transaction Documents (and including as exhibits to such Current Report on Form 8-K the material Transaction Documents, including,
without limitation, this Agreement and the Registration Rights Agreement). Each Purchaser, severally and not jointly with the other
Purchasers, covenants that it will comply with the provisions of any confidentiality or nondisclosure agreement executed by it
and, in addition, until such time as the transactions contemplated by this Agreement are required to be publicly disclosed by the
Company as described in this Section 4.7, such Purchaser will maintain the confidentiality of all disclosures made to it
in connection with this transaction (including the existence and terms of this transaction).


 


Article
5

CONDITIONS PRECEDENT TO CLOSING


 


5.1    
      Conditions Precedent to the Obligations of the Purchasers to Purchase Shares at the Closing.
The obligation of each Purchaser to acquire Shares at the Closing is subject to the fulfillment, on or prior to the Closing Date,
of each of the following conditions, any of which may be waived by such Purchaser (as to itself only): 


 


(a)              
Representations and Warranties. The representations
and warranties made by the Company in Section 3.1 shall be true and correct in all material respects (except for those representations
and warranties which are qualified as to materiality, in which case such representations and warranties shall be
true and correct in all respects) as of the date when made and as of the Closing Date, as though made on and as of such date, except
for such representations and warranties that speak as of a different specified date.


 


(b)              
Performance. The Company shall have performed, satisfied
and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be
performed, satisfied or complied with by it at or prior to the Closing.


 






    25


    


    

 


(c)               
No Injunction. No statute, rule, regulation, executive
order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority
of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents.


 


(d)              
Consents. The Company shall have obtained in a timely
fashion any and all consents, permits, approvals, registrations and waivers necessary for consummation of the purchase and sale
of the Shares at the Closing (including all Required Approvals, except for those set forth in clauses (i), (ii) and (iii) of Section 3.1(e),
which may be obtained after the Closing), all of which shall be and remain so long as necessary in full force and effect.


 


(e)               
No Suspensions of Trading in Common Stock. The Common
Stock shall not have been suspended, as of the Closing Date, by the Commission.


 


(f)                
Company Deliverables. The Company shall have delivered
the Company Deliverables in accordance with Section 2.2(a). 


 


(g)              
Termination. This Agreement shall not have been terminated
in accordance with Section 6.16 herein.


 


5.2    
Conditions Precedent to the Obligations of the Company to sell Shares at the Closing.
The Company’s obligation to sell and issue the Shares to each Purchaser at the Closing is subject to the fulfillment on or
prior to the Closing Date of the following conditions, any of which may be waived by the Company: 


 


(a)              
Representations and Warranties. The representations
and warranties made by such Purchaser in Section 3.2 hereof shall be true and correct in all material respects (except
for those representations and warranties which are qualified as to materiality, in which case such representations and warranties
shall be true and correct in all respects) as of the date when made, and as of the Closing Date as though made on and as of such
date, except for representations and warranties that speak as of a different specified date.


 


(b)              
Performance. Such Purchaser shall have performed,
satisfied and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents
to be performed, satisfied or complied with by such Purchaser at or prior to the Closing Date.


 


(c)               
No Injunction. No statute, rule, regulation, executive
order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority
of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by
the Transaction Documents.


 


(d)              
Purchaser Deliverables. Such Purchaser shall have
delivered its Purchaser Deliverables in accordance with Section 2.2(b). 


 


(e)               
Consents. Such Purchaser shall have obtained in a
timely fashion any and all consents, permits, approvals, registrations and waivers necessary from any governmental authorities
necessary for consummation of the purchase and sale of the Shares at the Closing.


 


(f)                
Termination. This Agreement shall not have been terminated
in accordance with Section 6.16 herein.


 






    26


    


    

 


Article
6



MISCELLANEOUS


 


6.1             
   Fees and Expenses. Except as expressly set forth
in the Transaction Documents to the contrary, the Company and the Purchasers shall each pay the fees and expenses of their respective
advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party in connection with the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees,
stamp taxes and other taxes and duties levied in connection with the sale and issuance of the Shares
to the Purchasers.


 


6.2             
 Entire Agreement. The Transaction Documents, together
with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter thereof
and supersede all prior agreements, understandings, discussions and representations, oral or written, with respect to such matters,
which the parties acknowledge have been merged into such documents, exhibits and schedules. At or after the Closing, and without
further consideration, the Company and the Purchasers will execute and deliver to the other such further documents as may be reasonably
requested in order to give practical effect to the intention of the parties under the Transaction Documents. 


 


6.3             
  Notices. Any and all notices or other communications
or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the
earliest of (a) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number
specified in this Section prior to 5:00 p.m., Boston time, on a Trading Day, (b) the next Trading Day after the date of transmission,
if such notice or communication is delivered via facsimile at the facsimile number specified in this Section on a day that is not
a Trading Day or later than 5:00 p.m., Boston time, on any Trading Day, (c) the Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service with next day delivery specified, or (d) upon actual receipt
by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows:



 





	 	If to the Company:	Corindus Vascular Robotics, Inc.
	 	 	309 Waverley Oaks Road, Suite 105
	 	 	Waltham, MA 02452
	 	 	Telephone No.: (508) 653-3335
	 	 	Facsimile No.: (508) 232-6000
	 	 	Attention: Chief Executive Officer
	 	 	 
	 	With a copy to:	 
	 	 	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	 	 	One Financial Center
	 	 	Boston, Massachusetts 02111
	 	 	Telephone No.: (617) 348-1799
	 	 	Facsimile No.: (617) 542-2241
	 	 	Attention: William C. Hicks, Marc D. Mantell




  


 To the address
set forth under such Purchaser’s name on its signature page hereto.  


 


or such other address as may be designated
in writing hereafter, in the same manner, by such Person.


 






    27


    


    

 


6.4             
 Amendments; Waivers; No Additional Consideration.
No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by
the Company and the Purchasers holding or having the right to acquire at least a majority of the Shares to be purchased at the
Closing or then outstanding or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought; provided,
however, that the Company may amend Exhibit A (without the consent of the Purchasers holding or having the right
to acquire at least a majority of the Shares to be purchased at the Closing or then outstanding) solely for the purposes of adding
additional Purchasers prior to the Closing Date. No waiver of any default with respect to any provision, condition or requirement
of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent
default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to
exercise any right hereunder in any manner impair the exercise of any such right. 


 


6.5               
Construction. The headings herein are for convenience
only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. The language
used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of
strict construction will be applied against any party. This Agreement shall be construed as if drafted jointly by the parties,
and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions
of this Agreement or any of the Transaction Documents.


 


6.6               
Successors and Assigns. The provisions of this Agreement
shall inure to the benefit of and be binding upon the parties and their successors and permitted assigns. This Agreement, or any
rights or obligations hereunder, may not be assigned by the Company without the prior written consent of the Purchasers (other
than by merger or consolidation or to an entity which acquires the Company, including by way of acquiring all or substantially
all of the Company’s assets). Any Purchaser may assign its rights hereunder in whole or in part to any Person to whom such
Purchaser assigns or transfers any Shares in compliance with the Transaction Documents and applicable law, provided such transferee
shall agree in writing to be bound, with respect to the transferred Shares, by the terms and conditions of this Agreement that
apply to the Purchasers.


 


6.7             
  No Third-Party Beneficiaries. This Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor
may any provision hereof be enforced by, any other Person.


 


6.8             
 Governing Law. All questions concerning the construction,
validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the
internal laws of the State of Delaware, without regard to the principles of conflicts of law thereof. Each party agrees that all
Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any
other Transaction Documents (whether brought against a party hereto or its respective Affiliates, employees or agents) shall be
commenced exclusively in the Boston Courts. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the Boston
Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees
not to assert in any Proceeding, any claim that it is not personally subject to the jurisdiction of any such Boston Court, or that
such Proceeding has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably waives personal service
of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail
or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HERETO HEREBY IRREVOCABLY
WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT
OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.


 






    28


    


    

 


6.9             
   Survival. The representations and warranties contained
herein shall survive the Closing and the delivery of the Shares for a period of one (1) year from the Closing Date. Covenants to
be performed after the Closing shall survive until performed or observed in accordance with their terms.


 


6.10         
 Execution. This Agreement may be executed in two
or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective
when counterparts have been signed by each party and delivered to the other party, it being understood that the parties need not
sign the same counterpart. In the event that any signature is delivered by facsimile transmission, or by e-mail delivery of a “.pdf”
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original
thereof.


 


6.11         
 Severability. If any provision of this Agreement
is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of
this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable
provision that is a reasonable substitute therefor and achieves that same or substantially the same effect or result, and upon
so agreeing, shall incorporate such substitute provision in this Agreement.


 


6.12         
 Remedies. In addition to being entitled to exercise
all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled
to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation
for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agree to waive in any
action for specific performance of any such obligation (other than in connection with any action for a temporary restraining order)
the defense that a remedy at law would be adequate.


 


6.13         
 Payment Set Aside. To the extent that the Company
makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights
thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated,
declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise
restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law,
state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part
thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not
been made or such enforcement or setoff had not occurred.


 


6.14         
 Adjustments in Share Numbers and Prices. In the event
of any stock split, subdivision, dividend or distribution payable in shares of Common Stock (or other securities or rights convertible
into, or entitling the holder thereof to receive directly or indirectly shares of Common Stock), reverse stock split, combination
or other similar recapitalization or event occurring after the date hereof, each reference in any Transaction Document to a number
of shares or a price per share shall be deemed to be amended to appropriately account for such event.


 






    29


    


    

 


6.15         
 Waiver of Conflicts. Each Purchaser acknowledges
that: (a) it has read this Agreement; (b) it has been represented in the preparation, negotiation and execution of this Agreement
by legal counsel of its own choice or has voluntarily declined to seek such counsel; and (c) it understands the terms and consequences
of this Agreement and is fully aware of the legal and binding effect of this Agreement. Each Purchaser understands that the Company
has been represented in the preparation, negotiation and execution of this Agreement by Mintz, Levin, Cohn, Ferris, Glovsky and
Popeo, P.C., Company Counsel, and that Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. has not represented any Purchaser or
any stockholder, director or employee of the Company in the preparation, negotiation and execution of this Agreement. Each Purchaser
acknowledges that Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. may have in the past represented and may now or may in the
future represent one or more Purchasers or their Affiliates in matters unrelated to the transactions contemplated by this Agreement,
including the representation of such Purchasers or their Affiliates in matters of a nature similar to those contemplated by this
Agreement. The Company and each Purchaser hereby acknowledge that they have has had an opportunity to ask for and have obtained
information relevant to such representation, including disclosure of the reasonably foreseeable adverse consequences of such representation,
and hereby waives any conflict arising out of such representation with respect to the matters contemplated by this Agreement.


 


6.16         
 Termination. This Agreement may be terminated and
the sale and purchase of the Shares abandoned at any time prior to the Closing by either the Company or any Purchaser (with respect
to itself only) upon written notice to the other, if the Closing has not been consummated on or prior to 5:00 p.m., Boston time,
on the Outside Date; provided, however, that the right to terminate this Agreement under this Section 6.16
shall not be available to any Person whose failure to comply with its obligations under this Agreement has been the primary cause
of or resulted in the failure of the Closing to occur on or before such time. Nothing in this Section 6.16 shall be deemed
to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other
Transaction Documents or to impair the right of any party to compel specific performance by any other party of its obligations
under this Agreement or the other Transaction Documents. Upon a termination in accordance with this Section 6.16, the Company
and the Purchaser shall not have any further obligation or liability (including arising from such termination) to the other. The
Company and Purchasers may extend the term of this Agreement in accordance with the amendment provisions of Section 6.4 herein.


 


[Remainder of Page Intentionally Left
Blank; Signature Page Follows]


 




    30


    


    


 








 


In
Witness Whereof, the parties hereto have caused this Common Stock
Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.


 





	 	COMPANY:
	 	 	 
	 	CORINDUS VASCULAR ROBOTICS, INC.
	 	 	 
	 	By:	 
	 	Name:
	 	Title:










 


[Signature Pages for Purchasers Follow]


 


[Signature Page to Securities Purchase Agreement]


 




     


     


    

 





	 	PURCHASER:
	 	 	 
	 	[____________________]
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	Aggregate Purchase Price (Subscription Amount):
	 	 
	 	Number of Shares of Common Stock to be Acquired:
	 	 
	 	 
	 	Address for Notice/Residency of Purchaser:
	 	 	 
	 	 	 
	 	 	 












	 	Telephone No.:	 	 
	 	Facsimile No.:	 
	 	E-mail Address:	 
	 	Attention:	 	 	 










 


Delivery Instructions:





(if different than above)


 





	c/o	 	 


 

	Street: 	 	 


 

	City/State/Zip:	 	 


 

	Attention:	 	 


 

	Telephone No.: 	 	 







 


[Signature Page to Securities Purchase Agreement]


 



     


     


    




 


EXHIBITS:


 


		A:	Schedule of Purchasers






		B	Form of Registration Rights Agreement






		C-1:	Accredited Investor Questionnaire






		C-2:	Stock Certificate Questionnaire






		D:	Form of Opinion of Company Counsel






		E:	Irrevocable Transfer Agent Instructions






		F:	Form of Secretary’s Certificate






		G:	Form of Compliance Certificate



 




     


     


    

 


Exhibit A


 


Schedule of Purchasers


 


	Purchaser	Subscription Amount
	 	 
	 	 
	 	 
	 	 
	 	 



 




    A-1


     


    

 


Exhibit C-1


 


Form of Accredited Investor
Questionnaire


 


ACCREDITED INVESTOR QUESTIONNAIRE





(ALL INFORMATION WILL BE TREATED CONFIDENTIALLY)


 


		To:	Corindus Vascular Robotics, Inc.



 


This Investor Questionnaire (“Questionnaire”)
must be completed by each potential investor in connection with the offer and sale of the shares of the common stock, par value
$0.0001 per share, (the “Securities”), of Corindus Vascular Robotics, Inc., a Delaware corporation (the
“Corporation”). The Securities are being offered and sold by the Corporation without registration under
the Securities Act of 1933, as amended (the “Act”), and the securities laws of certain states, in reliance
on the exemptions contained in Section 4(a)(2) of the Act and on Regulation D promulgated thereunder and in reliance on similar
exemptions under applicable state laws. The Corporation must determine that a potential investor meets certain suitability requirements
before offering or selling Securities to such investor. The purpose of this Questionnaire is to assure the Corporation that each
investor will meet the applicable suitability requirements. The information supplied by you will be used in determining whether
you meet such criteria, and reliance upon the private offering exemptions from registration is based in part on the information
herein supplied.


 


This Questionnaire does not constitute
an offer to sell or a solicitation of an offer to buy any security. Your answers will be kept strictly confidential. However, by
signing this Questionnaire, you will be authorizing the Corporation to provide a completed copy of this Questionnaire to such parties
as the Corporation deems appropriate in order to ensure that the offer and sale of the Securities will not result in a violation
of the Act or the securities laws of any state and that you otherwise satisfy the suitability standards applicable to purchasers
of the Securities. All potential investors must answer all applicable questions and complete, date and sign this Questionnaire.
Please print or type your responses and attach additional sheets of paper if necessary to complete your answers to any item.


 


		PART A.	BACKGROUND INFORMATION



 





	Name of Beneficial Owner of the Securities:	 







 





	Business Address:	 
	 	(Number and Street)



 


	(City)	(State)	(Zip Code)



 


	Telephone Number: (___)	







 





 


If a corporation, partnership, limited liability company,
trust or other entity: 


Type of entity:__________________





	State of formation: 	 	 	Approximate Date of formation:	 




 






    C-1-1


     


    

 


Were you formed for the purpose of
investing in the securities being offered?


 


Yes ____ No ____


 


If an individual:


 





	Residence Address:	 
	 	(Number and Street)


 





	(City)	(State)	(Zip Code)





 


Telephone Number: (____)___________


 


	Age:__________	Citizenship: ____________	Where registered
to vote: _______________









 


Set forth in the space provided below the
state(s), if any, in the United States in which you maintained your residence during the past two years and the dates during which
you resided in each state:


 


Are you a director or executive officer
of the Corporation?


 


Yes ____ No ____


 


Social Security or Taxpayer Identification No.: _________________________


 


		PART B.	ACCREDITED INVESTOR QUESTIONNAIRE



 


In order for the Corporation
to offer and sell the Securities in conformance with state and federal securities laws, the following information must be obtained
regarding your investor status. Please initial each category applicable to you as a Purchaser of Securities of the Corporation.


 


		___ (1)	A bank as defined in Section 3(a)(2) of the Securities
Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities Act whether acting
in its individual or fiduciary capacity;



 


		___ (2)	A broker or dealer registered pursuant to Section 15
of the Securities Exchange Act of 1934;



 


		___ (3)	An insurance company as defined in Section 2(a)(13)
of the Securities Act;



 


		___ (4)	An investment company registered under the Investment
Company Act of 1940 or a business development company as defined in Section 2(a)(48) of such act;



 


		___ (5)	A Small Business Investment Company licensed by the
U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958;



 






    C-1-2


     


    

 


		___ (6)	A plan established and maintained by a state, its political
subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if
such plan has total assets in excess of $5,000,000;



 


		___ (7)	An employee benefit plan within the meaning of the Employee
Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of
such act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the
employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely
by persons that are accredited investors;



 


		___ (8)	A private business development company as defined in
Section 202(a)(22) of the Investment Advisers Act of 1940;



 


		___ (9)	An organization described in Section 501(c)(3) of the
Internal Revenue Code, a corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose
of acquiring the Securities, with total assets in excess of $5,000,000;



 


		___ (10)	A trust, with total assets in excess of $5,000,000,
not formed for the specific purpose of acquiring the Securities, whose purchase is directed by a sophisticated person who has
such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks
of investing in the Corporation;



 


		___ (11)	A natural person whose individual net worth, or joint
net worth with that person’s spouse, at the time of his purchase exceeds $1,000,000 (excluding the value of such persons’
primary residence);



 


		___ (12)	A natural person who had an individual income in excess
of $200,000 in each of the two most recent years, or joint income with that person’s spouse in excess of $300,000, in each
of those years, and has a reasonable expectation of reaching the same income level in the current year;



 


		___ (13)	An executive officer or director of the Corporation;



 


		___ (14)	An entity in which all of the equity owners qualify
under any of the above subparagraphs. If the undersigned belongs to this investor category only, list the equity owners of the
undersigned, and the investor category which each such equity owner satisfies.



 


[Remainder of Page Intentionally Left
Blank; Signature Page Follows]


 




    C-1-3


     


    
 

		A.	FOR EXECUTION BY AN INDIVIDUAL:



 





	 	By	 	 
	 	 	 	 
	 	Date	 
	 	 	 
	 	Print Name:







 


		B.	FOR EXECUTION BY AN ENTITY:



 





	 	Entity Name: 	 



 


	 	By	 	 
	 	 	 	 
	 	Date	 
	 	 	 
	 	Print Name:



 


	 	Title:	 







 


		C.	ADDITIONAL SIGNATURES (if required by partnership, corporation or trust document):



 








	 	Entity Name: 	 



 


	 	By	 	 
	 	 	 	 
	 	Date	 
	 	 	 
	 	Print Name:



 


	 	Title:	 









 








	 	Entity Name: 	 



 


	 	By	 	 
	 	 	 	 
	 	Date	 
	 	 	 
	 	Print Name:



 


	 	Title:	 









 




     


     


    

 


Exhibit C-2


 


Form of Stock Certificate
Questionnaire


 


Stock Certificate Questionnaire


 


Pursuant to Section 2.2(b)(vi) of the Agreement, please provide
us with the following information:


 


1.       The exact name that
the Securities are to be registered in (this is the name that will appear on the stock certificate(s)). You may use a nominee name
if appropriate:


 





 






 





 






 





 






 


2.       The relationship
between the Purchaser of the Securities and the Registered Holder listed in response to Item 1 above:


 





 






 





 






 





 






 


3.       The mailing address,
telephone and telecopy number of the Registered Holder listed in response to Item 1 above:


 





 






 





 






 





 






 


4.       The Tax Identification
Number (or, if an individual, the Social Security Number) of the Registered Holder listed in response to Item 1 above:


 





 






 





 






 





 






 




    C-2-1


     


    

 


Exhibit E


 


Form of Irrevocable Transfer
Agent Instructions


 


CORINDUS VASCULAR ROBOTICS, INC.


 


February____, 2019


 


Manhattan Transfer Registrar Company





57 Eastwood Road





Miller Place, New York 11764





Attn: Ms. Desirée Carlo


 


Ladies and Gentlemen:


 


Reference is made to
that certain Securities Purchase Agreement, dated as of February ___, 2019 (the “Agreement”), by
and among Corindus Vascular Robotics, Inc., a Delaware corporation (the “Company”), and the purchasers
named therein (collectively, and including permitted transferees, the “Holders”), pursuant to which the
Company is issuing to the Holders shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”).


 


By this letter, you
are irrevocably authorized and directed to issue an aggregate of [●] shares of the Company’s Common Stock (the “Shares”).
The Shares should be issued in the names and denominations specified on Schedule I hereto, in either book entry or stock
certificate form, as indicated on Schedule I. The Shares have not been registered and are, therefore, “restricted
shares.” Accordingly, the Shares should bear the following restricted legend:


 


THESE SECURITIES HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES
MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION
OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.


 


The Shares are also
subject to certain restrictions on transfer in accordance with the Agreement during the six (6)-month period following the closing
of the sale of the Shares (the “Lock-Up Period”). Accordingly, the Shares should bear the following restricted
legend:


 


THE SHARES ARE SUBJECT TO A SIX (6)-MONTH
LOCK-UP PERIOD, AS SET FORTH IN A SECURITIES PURCHASE AGREEMENT AMONG THE COMPANY AND THE ORIGINAL HOLDER OF THESE SHARES, COPIES
OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY.


 






    E-1


     


    

 


The Shares may be issued
to any Holder in certificate form (each, a “Certificate” and collectively, the “Certificates”)
upon request. Any Certificate issued should contain the aforementioned legend.


 


This letter shall also
serve as our irrevocable authorization and direction to you (provided that you are the transfer agent of the Company at such time
and the conditions set forth in this letter are satisfied), subject to any stop transfer instructions that we may issue to you
from time to time, if any, to issue shares of Common Stock upon transfer or resale of the Shares.


 


You acknowledge and
agree that so long as (i) you have received written confirmation from the Company’s legal counsel that a registration statement
covering resales of the Shares has been declared effective by the Securities and Exchange Commission (the “Commission”)
under the Securities Act of 1933, as amended (the “Securities Act”), and a copy of such registration
statement, and (ii) the Lock-Up Period has expired, then, unless otherwise required by law, you shall use your commercially reasonable
efforts to issue the certificates representing the Shares registered in the names of such Holders or transferees, as the case may
be, within three (3) Business Days of your receipt of a notice of transfer of Shares, and such certificates shall not bear any
legend restricting transfer of the Shares thereby and should not be subject to any stop-transfer restriction.


 


A form of written confirmation
from the Company’s outside legal counsel that a registration statement covering resales of the Shares has been declared effective
by the Commission under the Securities Act (which confirmation shall be delivered to you upon effectiveness of the registration
statement) is attached hereto as Annex A.


 


Please be advised that
the Holders are relying upon this letter as an inducement to enter into the Agreement and, accordingly, each Holder is a third
party beneficiary to these instructions.


 


Please execute this letter in the space
indicated to acknowledge your agreement to act in accordance with these instructions.


 


[Remainder of Page Intentionally Left
Blank; Signature Page Follows]


 




    E-2


     


    

 





	 	Very truly yours,
	 	 	 
	 	CORINDUS VASCULAR ROBOTICS, INC.
	 	 	 
	 	By:	 
	 	Name: Mark J. Toland
	 	Title: Chief Executive Officer and President







 


Acknowledged and Agreed:


 


Manhattan Transfer Registrar Company


 





	By:	 	 	 	 
	Name:	 	 
	Title:	 	 	 







 





[Signature Page to Authorization Letter to Transfer Agent] 







 




     


     


    

 


Schedule
I


 


Holders


 


	Holders	Address	EIN	Common

Shares	Form
	[●]	[●]	[●]	[●] 	[●]



 




    Schedule I-1


     


    

 


Annex
A


 


FORM OF NOTICE OF EFFECTIVENESS OF REGISTRATION
STATEMENT


 


Manhattan Transfer Registrar Company





57 Eastwood Road





Miller Place, New York 11764





Attn: Ms. Desirée Carlo


 


Re: Corindus Vascular Robotics, Inc.


 


Ladies and Gentlemen:


 


Corindus Vascular Robotics,
Inc., a Delaware corporation (the “Company”), has entered into a Securities Purchase Agreement (the “Agreement”),
dated as of [●], 2019, with the buyers named therein (collectively, the “Purchasers”) pursuant
to which the Company issued to the Purchasers shares of the Company’s common stock, $0.0001 par value per share (the “Common
Stock”). Pursuant to that certain Registration Rights Agreement of even date, the Company agreed to register the
resale of the Common Stocks (the “Registrable Securities”), under the Securities Act of 1933, as
amended (the “Securities Act”). In connection with the Company’s obligations under the Registration
Rights Agreement, on [___], 2019, the Company filed a Registration Statement on Form S-3 (File No. 333-                    )
(the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”)
relating to the Registrable Securities which names each of the Purchasers as a selling stockholder thereunder and set forth as
Exhibit A hereto.


 


In connection with
the foregoing, we advise you that a member of the Commission’s staff has advised us by telephone that the Commission has
entered an order declaring the Registration Statement effective under the Securities Act at ____ [a.m.][p.m.] on [___], 2017, and
we have no knowledge, after telephonic inquiry of a member of the staff, that any stop order suspending its effectiveness has been
issued or that any proceedings for that purpose are pending before, or threatened by, the Commission and the Registrable Securities
are available for resale under the Securities Act pursuant to the Registration Statement. Based upon the foregoing, we are of the
opinion that as of the date of this opinion, the Registrable Securities have been duly authorized and, when issued by you, will
be validly issued, fully paid and non-assessable, and are registered for resale under the Securities Act under the effective Registration
Statement and, following the expiration of the Lock-Up Period (as defined in the Agreement), may be issued without a restrictive
legend.


 


This letter shall serve
as our standing notice to you that, following the expiration of the Lock-Up Period, the Common Stock may be freely transferred
by the Purchasers pursuant to the Registration Statement. You need not require further letters from us to effect any future legend-free
issuance or reissuance of shares of Common Stock upon the expiration of the Lock-Up Period to the Purchasers or the transferees
of the Purchasers, as the case may be, as contemplated by the Company’s Irrevocable Transfer Agent Instructions dated February
[●], 2019, provided at the time of such reissuance, the Company has not otherwise notified you that the Registration Statement
is unavailable for the resale of the Registrable Securities. This letter shall serve as our standing instructions with regard to
this matter.


 


[Remainder of Page Intentionally
Left Blank; Signature Page Follows]


 




    Annex A-1


     


    

 





	 	Very truly yours,
	 	 
	 	CORINDUS VASCULAR ROBOTICS, INC.
	 	 	 
	 	By:	 
	 	Name: Mark J. Toland
	 	Title: Chief Executive Officer and President







 


[Signature Page to
Notice of Effectiveness of Registration Statement]


 




     


     


    

 


Exhibit
A


 


Registration
Statement


 




    A-1


     


    

 





 


Exhibit F


 


Form of Secretary’s
Certificate


 


corindus
vascular robotics, Inc.


 


Secretary’s Certificate


 


February _____, 2019


 


The undersigned hereby
certifies that he is the duly elected, qualified and acting Secretary of Corindus Vascular Robotics, Inc., a Delaware corporation
(the “Company”), and that as such he is authorized to execute and deliver this certificate in the name
and on behalf of the Company, pursuant to Section 2.2(a)(v) of the Securities Purchase Agreement, dated as of February ____,
2019, by and among the Company and the purchasers party thereto (the “Securities Purchase Agreement”), and further certifies in his official capacity, in the name and on behalf of the Company, the items set
forth below. Capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Securities Purchase
Agreement.


 


		1.	Attached hereto as Exhibit A is a true, correct and complete copy of the resolutions duly
adopted by the Board of Directors of the Company and any duly authorized committee thereof at a meeting held on February 18, 2019
approving the transactions contemplated by the Securities Purchase Agreement and the other Transaction Documents and the issuance
of the Securities. Such resolutions have not in any way been amended, modified, revoked or rescinded, have been in full force and
effect since their adoption and are now in full force and effect and are the only resolutions adopted by the Board of Directors
of the Company or any duly authorized committee thereof relating to the transactions contemplated by the Transaction Documents.



 


		2.	Attached hereto as Exhibit B-1 is a true, correct and complete copy of the Certificate of
Incorporation of the Company, together with any and all amendments thereto, and no action has been taken to further amend, modify
or repeal such Certificate of Incorporation, the same being in full force and effect as of the date hereof. Attached hereto as
Exhibit B-2 is a true, correct and complete copy of the Bylaws of the Company, together with any and all amendments thereto,
and no action has been taken to further amend, modify or repeal such Bylaws, the same being in full force and effect as of the
date hereof.



 


		3.	Each person whose name appears on Exhibit C hereto is duly elected or appointed to the position(s)
indicated opposite his name and is duly authorized to sign the Transaction Documents and any related documents on behalf of the
Company, and the signature appearing opposite such person’s name is such person’s genuine signature.



 


[Remainder of Page Intentionally Left
Blank; Signature Page Follows]


 






    F-1


     


    

 


IN WITNESS WHEREOF,
the undersigned have executed this certificate as of the date first set forth above.


 





	 	By:	 	 
	 	Name: David W. Long	 
	 	Title: Secretary	 



  


I, Mark J. Toland,
Chief Executive Officer and President, hereby certify that David W. Long is the duly elected, qualified and acting Secretary of
the Company and that the signature set forth above is his true signature.


 





	 	By:	 	 
	 	Name: Mark J. Toland	 
	 	Title: Chief Executive Officer and President	 





 




    F-1


     


    


	


 


Exhibit A


 


Board Resolutions


 




    F-2


     


    


 


Exhibit B-1


 


Certificate of Incorporation


 




    F-3


     


    


 


Exhibit B-2


 


Bylaws


 




    F-4


     


    


 


Exhibit C


 


Certificate of Incumbency


 


	Name	Title	Signature
	Mark J. Toland	Chief Executive Officer and President	 
	David W. Long	Chief Financial Officer and Senior Vice President, Secretary and Treasurer 	 



 



    F-5


     


    


 


Exhibit G


 


Form of Compliance Certificate


 


Corindus
vascular robotics, Inc.


 


Compliance Certificate


 


February _____, 2019


 


The undersigned, the
Chief Executive Officer and President of Corindus Vascular Robotics, Inc., a Delaware corporation (the “Company”),
pursuant to Section 2.2(a)(vi) of the Securities Purchase Agreement, dated as of February ___, 2019, by and among the Company and
Purchasers (as defined therein) (the “Securities Purchase Agreement”), hereby represents, warrants
and certifies as follows (capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Securities
Purchase Agreement):


 


		1.	The representations and warranties made by the Company in Section 3.1 of the Securities Purchase
Agreement are true and correct in all material respects (except for those representations and warranties which are qualified as
to materiality, in which case such representations and warranties are true and correct in all respects) as of the date when made
and as of the date hereof, as though made on and as of such date, except for such representations and warranties that speak as
of a different specified date.



 


		2.	The Company has performed, satisfied and complied in all material respects with all covenants,
agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to
the date hereof.



 


[Remainder of Page Intentionally Left
Blank; Signature Page Follows]


 




    G-1


     


    


 


IN WITNESS WHEREOF,
the undersigned has executed this certificate as of the date first set forth above.


 





	 	 	 
	 	Mark J. Toland	 
	 	Chief Executive Officer and President	 


 






    G-2